fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

CHMP positive for seladelpar for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid – Gilead Sciences

Written by | 25 Feb 2025

Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending seladelpar for the… read more.

Penmenvy, meningococcal vaccine, approved by FDA to help protect against MenABCWY – GSK

Written by | 24 Feb 2025

GSK plc announced that the FDA has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25 years. The… read more.

CHMP recommends Tivdak (tisotumab vedotin) to treat recurrent or metastatic cervical cancer – Pfizer

Written by | 22 Feb 2025

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Tivdak, ( tisotumab vedotin) intended for the… read more.

Omvoh (mirikizumab-mrkz) for Crohn’s disease achieved sustained clinical remission and endoscopic response at two years for most patients – Eli Lilly

Written by | 21 Feb 2025

Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn’s disease receiving two years… read more.

Imfinzi (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer – AstraZeneca

Written by | 20 Feb 2025

AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following… read more.

FDA approval for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for subcutaneous injection – BMS

Written by | 19 Feb 2025

The FDA has  approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig, Bristol Myers Squibb Company) for subcutaneous injection across approved adult, solid tumor nivolumab (Opdivo, Bristol Myers Squibb Company) indications… read more.

Bayer files for approval of finerenone in heart failure in Japan

Written by | 18 Feb 2025

Bayer announced the submission of a marketing authorization application to the Ministry of Health, Labour, and Welfare (MHLW) in Japan, seeking approval of finerenone in adult patients with… read more.

Submission of twos BLAs at FDA for Tremfya (guselkumab) for juvenile patients in plaque psoriasis and juvenile psoriatic arthritis – Johnson & Johnson

Written by | 17 Feb 2025

Johnson & Johnson  announced the submission of two supplemental Biologics License Applications (sBLAs) to the FDA seeking approval of Tremfya (guselkumab) for the treatment of children 6 years… read more.

Nucala (mepolizumab) approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps – GSK

Written by | 16 Feb 2025

GSK plc announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with intranasal corticosteroids… read more.

The FDA has approved Emblaveo (aztreonam and avibactam) for the treatment of complicated intra-abdominal infections (cIAI) – AbbVie

Written by | 15 Feb 2025

AbbVie announced that the FDA has approved Emblaveo (aztreonam and avibactam), as the first and only fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination antibiotic. It is approved in combination with… read more.

MHRA (UK) has granted a conditional marketing authorisation to Imdylltra (tarlatamab) for the treatment of extensive-stage small cell lung cancer – Amgen

Written by | 14 Feb 2025

Amgen announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation to Imdylltra for the treatment of adult patients with extensive-stage… read more.

FDA approves Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults – Axsome Therapeutics

Written by | 13 Feb 2025

Axsome Therapeutics, Inc. announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. Symbravo represents a novel… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.